Company news
Amarantus Bioscience Holdings, Inc. news in 2019
Amarantus Bioscience Holdings, Inc.'s news releases, calls and decks from 2019, newest first.
Amarantus to Present at 12th Annual LD Micro Main Event
December 9, 2019
Todos To Present At Upcoming 12th Annual LD Micro Main Event
December 6, 2019
Amarantus Subsidiary Elto Pharma Receives Notice of Allowance Covering Use of Eltoprazine Combined with CBD to Treat Parkinson’s Disease
December 4, 2019
Amarantus Announces Issuance of Chinese Patent Covering the Use of MANF and CDNF in Retinal Disorders for Subsidiary MANF Therapeutics
November 21, 2019
Amarantus Provides Recapitalization Update to Shareholders
November 18, 2019
Todos and Amarantus JV Announces Full Enrollment for Clinical Trial of LymPro Alzheimer’s Blood Test Relationship with Amyloid PET
November 14, 2019
Emerald Organic Products to License Therapeutics Portfolio from Amarantus Bioscience Holdings
October 25, 2019
Amarantus Enters Into Agreement to License Diverse Therapeutics Portfolio to CBD-focused Emerald Organic Products
October 24, 2019
Todos Medical and Orot+ Announce First Patient Enrolled in Pre-Commercial Launch Preparations of TM-B1 and TM-B2 Breast Cancer Blood Screening Tests in Europe
September 24, 2019
Amarantus Enters into Letter of Intent with The Alchemists Kitchen to Establish Joint Venture for Research and Commercialization of Hemp and Herbal Smokables for Addiction Treatment Including Smoking Cessation
June 25, 2019
Amarantus Announces Positive Pre-Clinical Data for MANF in Wolfram Syndrome Presented at the 79th Annual Scientific Sessions of the American Diabetes Association
June 18, 2019
Amarantus Announces Issuance of US Patent No. 10,195,251 Covering MANF Treatment of Wolfram's Syndrome, Retinitis Pigmentosa, and Glaucoma for Subsidiary MANF Therapeutics
June 13, 2019
Amarantus to Present at 9th Annual LD Micro Invitational Conference
June 4, 2019
Amarantus Engages Evolution Venture Partners to Evaluate Strategic Alternatives for Expansion into the Emerging Legal Hemp Industry
May 28, 2019
Todos Medical Exercises Option to Acquire Remaining 80.01% of Breakthrough Diagnostics from Amarantus After Review of Alzheimer's Blood Test Data
May 28, 2019
Todos Medical Raises $1,350,500 In Funding and Finalizes Joint Venture Agreement with Amarantus Bioscience
February 28, 2019
MANF Therapeutics Receives Notices of Allowance Covering MANF Use as Treatment for Parkinson's in Europe and Diabetes in Japan
January 17, 2019
MANF Therapeutics Receives Notice of Allowance from US Patent & Trademark Office Covering the Use of MANF or CDNF as a Treatment for Glaucoma, Macular Degeneration and Retinitis Pigmentosa
January 15, 2019
Amarantus Announces Commercialization Partnership With IDEA Pharma for Subsidiaries
January 11, 2019
Amarantus Provides 2019 Roadmap
January 7, 2019